

CURRICULUM VITAE

Name:

Gregory A. Curt, M.D.



Education:

- 1970-1973** **B.S. *Summa Cum Laude*, Biology, Providence College, Providence, Rhode Island**
- 1973-1977** **M.D. *With Distinction in Research*, University of Rochester School of Medicine, Rochester, New York**
- 1977-1980** **Internship and Residency in Internal Medicine, New England Deaconess Hospital, Harvard Medical School, Boston, Massachusetts**
- 1980-1983** **Fellow, Medical Oncology, National Cancer Institute, Bethesda, MD**

Brief Chronology of Employment:

- 1974** **Gordon and Viola Leak Research Fellow (ACS), Childrens Cancer Research Foundation, The Jimmy Fund Building), Boston, MA (Advisor, Dr. Sidney Farber)**
- 1975-1976** **Gordon and Viola Leak Research Fellow (ACS), Charing Cross Hospital, London, England (with Dr. —————) (Summers inclusive)**
- 1977-1980** **Fellow in Medicine, Harvard Medical School, Boston, MA**
- 1979-1980** **Research Fellow, Peter Bent Brigham Hospital, Boston, MA**
- 1980-1981** **Fellow and Clinical Associate, Medicine Branch, National Cancer Institute, Bethesda, MD**
- 1981-1983** **Fellow and Clinical Associate, Clinical Pharmacology Branch, National Cancer Institute, Bethesda, MD**
- 1983-1984** **Special Assistant for Clinical Affairs, Office of the Director, Division of Cancer Treatment, National Cancer Institute, Bethesda, MD**
- 1984-1985** **Assistant Director, Division of Cancer Treatment, National Cancer Institute, Bethesda, MD**
- 1985-1988** **Deputy Director, Division of Cancer Treatment, National Cancer Institute, Bethesda, MD**
- 1988- 1989** **Director of Medical Education and Chief of Clinical Pharmacology, Roger Williams Hospital, Brown University, Providence, RI**
- 1989-1995** **Associate Director, Clinical Oncology Program, National Cancer Institute, Bethesda, MD**

1995-2002 Deputy Director for Clinical Affairs, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD

1989-2002 Clinical Director, National Cancer Institute, Bethesda, MD

2002-2004 Medical Director, AstraZeneca Medical Affairs
 Medical Liaison, Emerging Products, AstraZeneca Oncology
 Alliance Manager for NCI/NIH, AstraZeneca Medical Affairs
 Guest Researcher – NCI Division of Clinical Sciences

2004 –2006
 Senior Medical Director, AstraZeneca Medical Affairs
 Medical Liaison, Emerging Products, AstraZeneca Oncology
 Alliance Manager for NCI/NIH, AstraZeneca Medical Affairs
 Guest Researcher – NCI Division of Clinical Sciences

2007 – present
 U.S. Medical Science Lead, Emerging Products, AstraZeneca Oncology
 Board Member, C-Change

Professional Certification:

Diplomate, American Board of Internal Medicine, September 1980
 Diplomate, American Board of Clinical Oncology, September 1983

Academic Honors, Activities:

Providence College	1973 -	Bachelor of Science, Summa Cum Laude, Member, Secretary Alpha Epsilon Delta (Pre-medical Honor Society)
University of Rochester School of Medicine and Dentistry	1977 -	Doctor of Medicine with Distinction in Research; Robert Kates Award (to graduating student with demonstrated excellence in clinical medicine and research); Member, Alpha Omega Alpha National Medical Honor Society
New England Deaconess Hospital	1978 -	Baron von Munchhausen Award; Outstanding Intern in Emergency Medicine
	1979 -	Outstanding Resident in Internal Medicine
	1979 - 1980 -	Member, Human Studies Committee; Committee on Clinical Research; Scientific Review Subcommittee

1985 - James L. Tullis Lectureship Prize for Original Study in Research

National Cancer Institute (NCI), National Institutes of Health (NIH)

1982 - 1988 -	Member, Clinical Oncology Review Committee, Cancer Therapy Evaluation Program, DCS, NCI
1984 - 1988 -	Member Ex Officio, Decision Network Committee, DCT, NCI
1984 - 1988	Chief of Program Directors (Overseeing Grant Portfolio), Division of Cancer Treatment, NCI
1984-1988	Chief of Project Officers (Overseeing Contract Portfolio), Division of Cancer Treatment, NCI
1992 - 1994	Chairman, Medical Board, NIH Clinical Center
1995- 2002	Director, Protocol Resource Office
1996- 2002	Chairman, Protocol Review and Monitoring Committee
2002-2003	Chairman, Medical Executive Committee, NIH Clinical Center

Awards:

1988 - Unit Commendation (PHS)

1992 - Outstanding Service Medal (PHS)

1993 - EEO Officer's Achievement Award

Editorial Responsibilities:

Editorial Board, CANCER TREATMENT REPORTS, 1985-1988

Founding Editor, THE ONCOLOGIST - 1995

Founding CME Editor, THE ONCOLOGIST 1998-present

Reviewer: CANCER RESEARCH, CLINICAL CANCER RESEARCH, JAMA

Corporate Roles:

Contributing Partner, The National Dialog on Cancer (C-Change)

2002-Present

Ad Hoc Member, CEO Roundtable (C-Change)

2002-Present

BIBLIOGRAPHY

Gregory A. Curt, M.D.

1. Curt, G.A., Tobias, J.S., Parker, L.M., Kramer, R.A., Rosowsky, A., and Tattersall, M.H.N.: Cellular pharmacology of the di-n-butyl ester of methotrexate. *J. Clin. Pharmacol.* 15: 556-557, 1975.
2. Curt, G.A., Tobias, J.S., Kramer, R.A., Rosowsky, A., Parker, L.M. and Tattersall, M.H.N.: Inhibition of nucleic acid synthesis by the butyl ester of methotrexate. *Biochem. Pharmacol.* 25: 1943-1946, 1976.
3. Curt, G.A., Connors, T.A., Murray-Lyon, I.M. and Tattersall, M.H.N.: Clinical pharmacology of a hepatoma-specific alkylating agent. *Biochem. Pharmacol.* 26: 1715-1718, 1977.
4. D'Elia, J.A., Curt, G.A., Kaldany, A., Trey, C., Falchuk, K.R., and Weinrauch, L.A.: Risk of acute renal failure following angiography in the elderly. *Angiology* 30: 205-207, 1979.
5. Curt, G.A., Kaldany, A., Whitley, L.G., Crosson, A.W., Rolla, A. and D'Elia, J.A.: Acute renal failure induced by non-steroidal anti-inflammatory drugs. *An. Intern. Med.* 1: 72-73, 1980.
6. Richardson, V.J., Curt, G.A. and Ryman, B.E.: Liposomally entrapped ara-CTP to overcome ara-C resistance in a murine lymphoma in vitro. *Brit. J. Cancer* 45: 559-563, 1982.
7. Jolivet, J., Curt, G.A., Clendeninn, N.J. and Chabner, B.A.: Antimetabolites. In *Cancer Chemotherapy Annual*, Vol. 4, Pinedo, H.M. (Ed.), pp. 1-28, Elsevier, New York, 1982.
8. Kaldany, A., Curt, G.A., Estes, M.N., Weinrauch, L.A., Christlieb, A.R. and D'Elia, J.A.: Reversible acute pulmonary edema due to uncontrolled hyperglycemia in diabetic individuals with renal failure. *Diabetes Care* 5: 506-511, 1983.
9. Curt, G.A., Carney, D.N., Cowan, K.H., Jolivet, J., Bailey, B.D., Drake, J.C., Kao-Shan, C.S., Minna, J.D. and Chabner, B.A.: Unstable methotrexate resistance in human small cell cancer associated with double minute chromosomes. *N. Engl. J. Med.* 308: 199-202, 1983.

10. Jolivet, J., Curt, G.A., Clendeninn, N.J., Yeh, G.C. and Chabner, B.A.: Antimetabolites. In Cancer Chemotherapy Annual, Vol. 5, Pinedo, H.M. (Ed.), Excerpta Medica, Amsterdam, pp. 1-29, 1983.
11. Shoemaker, R., Carney, D.N. and Curt, G.A.: Evidence for multiple drug resistance in human tumor cells lines. *Cancer Treat. Rep.* 67: 883-888, 1983.
12. Curt, G.A., Grygiel, J., Corden, B., Ozols, R., Weiss, R., Tell, D.T., Myers, C.E. and Collins, J.M.: A phase I and pharmacokinetic study of CBDCA, carboplatin. *Cancer Res.* 43: 4470-4473, 1983.
13. Curt, G.A., Kelley, J.A., Kufta, C.V., Smith, B.H., Cornblith, P.L., Young, R.C. and Collins, J.M.: A phase II and pharmacokinetic study of azididinybenzoquone (AZQ) in high grade glioma. *Cancer Res.* 43: 6102-6105, 1983.
14. Jolivet, J., Cowan, K.H., Curt, G.A., Clendeninn, N.J. and Chabner, B.A.: The pharmacology and clinical use of methotrexate. *N. Engl. J. Med.* 309: 1094-1104, 1983.
15. Chabner, B.A., Clendeninn, N.J. and Curt, G.A.: Introduction to symposium on drug resistance. *Cancer Treat. Rep.* 67: 855-857, 1983.
16. Clendeninn, N.J., Jolivet, J., Curt, G.A., Cysyk, R.L., Myers, C.E. and Chabner, B.A.: Cytotoxic drugs active in leukemia. In The Leukemias, Goldman, J.M. and Preisler, H.D. (Eds.), Butterworth and Co., London, pp. 35-103, 1984..
17. Curt, G.A., Cowan, K.H. and Chabner, B.A.: Drug resistance in cancer. *Cancer Treat. Rep.* 68: 87-99, 1984.
18. Curt, G.A., Cowan, K.H. and Chabner, B.A.: Gene amplification in drug resistance: Of mice and men. *J. Clin. Oncol.* 2: 6264, 1984.
19. Curt, G.A., Jolivet, J. Bailey, B.D., Carney, D.N. and Chabner, B.A.: Synthesis and retention of methotrexate polyglutamates by human small cell lung cancer. *Biochem. Pharmacol.* 33: 1682-1685, 1984.
20. Chabner, B.A., Curt, G.A. and Hubbard, S.M.: Editorial: Surgical oncology research development: The perspective of the National Cancer Institute. *Cancer Treat. Rep.* 68: 825-829, 1984.
21. Chabner, B.A., Fine, R.L. Allegra, C.J., Yeh, G.C. and Curt, G.A.: Cancer chemotherapy: Progress and expectations, 1984. *Cancer* 54: 2599-2608, 1984.
22. Curt, G.A., Allegra, C., Fine, R.L., Yeh, G.C., Jolivet, J. and Chabner, B.A.: Antimetabolites. In Cancer Chemotherapy annual, Vol. 6, Pinedo, H.M. and

- Chabner, B.A. (Eds.), Elsevier, Amsterdam, pp. 1-30, 1984..
23. Curt, G.A., Jolivet, J., Carney, D.N., Bailey, B.D., Drake, J.C., Clendeninn, N. and Chabner, B.A.: Determinants of the sensitivity of human small cell lung cancer cell lines to methotrexate. *J. Clin. Invest.* 76: 1323-1329, 1985.
 24. Koizumi, S., Curt, G.A., Fine, R.L., Griffin, J.D. and Chabner, B.A.: Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow. *J. Clin. Invest.* 75: 1008-1013, 1985.
 25. Koizumi, S., Fine, R.L., Curt, G.A., Griffin, J.D. and Chabner, B.A.: Purification of myeloid progenitor cells (CFU-Cs) from normal human bone marrow using an immune-rosette technique. *Exper. Hematol.* 13: 560-565, 1985.
 26. Chabner, B.A., Allegra, C.J., Curt, G.A., Clendeninn, N.J., Baram, J., Koizumi, S. and Jolivet, J.: The polyglutamation of methotrexate: Is methotrexate a prodrug? *J. Clin. Invest.* 76: 907-912, 1985.
 27. Clendeninn, N.J., Curt, G., Allegra, C.J., Yeh, G.C., Baram, J. and Chabner, B.A.: Antimetabolites. In Pinedo, H.M. and Chabner, B.A. (Eds.), *Cancer Chemotherapy Annual 7*, Elsevier, Amsterdam, pp. 1-30, 1985.
 28. Lokich, J.J. and Curt, G. A.: A phase I and pharmacology study of continuous-infusion low-dose methotrexate administration. *Cancer* 56: 2391-2394, 1985.
 29. Lokich, J.J., Phillips, D., Green, R., Paul, S., Sonneborn, H., Zipoli, T.E. and Curt, G.A.: 5-fluorouracil and methotrexate administered simultaneously as a continuous infusion. A phase I study. *Cancer* 56: 2395-2398, 1985.
 30. Chabner, B.A., Curt, G.A. and Fine, R.L.: Drug resistance: A primary obstacle to progress in chemotherapy. In Fortner, J.G. and Roads, J.E., *Accomplishments in Cancer Research 1984*, J.B. Lippincott, Philadelphia, pp. 241-245, 1985.
 31. Curt, G.A., Kelley, J.A., Fine, R.L., Huguenin, P.N., Roth, J.S., Batist, G., Jenkins, J. and Collins, J.M.: A phase I and pharmacokinetic study of dihydro-5-azacytidine (NSC-264880). *Cancer Res.* 45: 3359-3363, 1985.
 32. Drake, J.C., Allegra, C.J., Curt, G.A. and Chabner, B.A.: Competitive protein binding assay for trimetrexate. *Cancer Treat. Rep.* 69: 641-644, 1985.
 33. Curt, G.A. and Chabner, B.A.: Drug resistance in colon cancer. In Mastromarino, A.J. (Ed.), *Biology and Treatment of Colorectal Cancer Metastasis*. Martinus Mijhoff Publishing, Boston, pp. 281-293. 1986.
 34. Curt, G.A., Katterhagen, G. and Mahaney, F.X.: Immunoaugmentative therapy: a primer on the perils of unproved treatments. *J. Am. Med. Assoc.* 255: 505-507,

1986.

35. Chabner, B., Clendeninn, N.J., Curt, G.A. and Jolivet, J.: Biochemistry of methotrexate. In Kimura, J. and Wang, Y.M. (Eds.), *Methotrexate in Cancer Therapy*, Raven Press, New York, pp. 1-38, 1986.
36. Perry, D.L., Weiss, R.B., Creekmore, S.O., Micetich, K.C. and Curt, G.A.: Carboplatin for advanced colorectal carcinoma: a phase I study. *Cancer Treat. Rep.* 70: 301-302, 1982.
37. Weiss, R.B., James, W.D., Major, W.B., Porter, M.B., Allegra, C.J. and Curt, G.A.: Skin reactions induced by trimetrexate, and analog of methotrexate. *Invest. New Drugs* 4: 159-163, 1986.
38. Curt, G.A., Allegra, C.J., Fine, R.L., Yeh, G.C., Mjuagic, H. and Chabner, B.A.: Cancer chemotherapy. In Ullman's Encyclopedia, Vol. A5, VCH Verlagsgesellschaft, Weinheim, pp. 1-28, 1986.
39. Ozols, R.F., Ostchega, Y., Curt, G. A. and Young, R.W.: High-dose carboplatin in refractory ovarian cancer patients. *J. Clin. Oncol.* 5: 197-201, 1987.
40. Fine, R.L., Koizumi, S., Curt, G.A. and Chabner, B.A.: Effect of calcium channel blockers on human CRU-GM with cytotoxic drugs. *J. Clin. Oncol.* 5: 489-495, 1987.
41. Curt, G.A., Cheson, B.D. and Allegra, C.J.: Cytosine arabinoside. In Lokich, J.J. (Ed.), *Infusional Chemotherapy*, Precept Press, Chicago pp. 161-166, 1987.
42. Allegra, C.J. and Curt, G.A.: Methotrexate. In Lokich, J.J. (Ed.), *Infusional Chemotherapy*, Precept Press, Chicago pp. 123-129, 1987.
43. Curt, G.A. and Chabner, B.A.: Medical oncology: decade of discovery. *Internal Medicine for the Specialist* Vol. 8, No. 8: 74-84, 1987.
44. Allegra, C.J., Baram, J., Chabner, B., Yeh, G.C., Aiba, K. and Curt, G.A.: Antimetabolites. In Pinedo, H.M., Longo, D.L. and Chabner, B.A. (Eds.), *Cancer Chemotherapy and Biological Response Modifiers*, Annual 9. Elsevier, Amsterdam pp. 1-22, 1987.
45. Curt, G.A. and Allegra, C.J.: Methotrexate resistance: mechanisms and implications. In Kessel, D. (Ed.), *Drug Resistance*, CRC Press, pp. 369-384, 1989.
46. Curt, G.A. and Chabner, B.A.: Treatment research in cancer. In *Cancer Growth and Progression*, (Kaiser, H.E., Series Editors); *Fundamental Aspects of Cancer*, (Goldfarb, R.H., Editor). Kluwer Academic Publishers, Dordrecht, pp. 162-170, 1989.

47. Posner, M., Slapak, C.A., Browne, M.J., Clark, J.W., Curt, G.A., Weitberg, A., Colubris, P., Cummings, F.J., Weimann, M., Surba, S. and Robert, N.J.: A phase I-II trial of continuous-infusion cisplatin, continuous infusion 5-fluorouracil, and VP-16 in colorectal carcinoma. *AM. J. Clin., Oncol.* pp. 455-458, 1990.
48. Curt, G.A.: unsound methods of cancer treatment. In DeVita, V.T., Hellman, S. and Rosenberg, S.A. (Eds.), *Principles and Practice of Oncology Updates Vol.4 No. 12*: pp. 1-10, 1990.
49. Curt, G.A. and Collins, J.M.: The clinical pharmacology of infusional chemotherapy. In *Cancer Chemotherapy by Infusion*, (Lokich, J., ed.) Pluribus Press, Inc. 1990.
50. Posner, M.R., Darnowski, J.W., Calabresi, P., Brunetti, I., Corvese, D., Curt, G.A., Cummings, F.J., Clark, J., Browne, M.J., Beitz, J. and Weitberg, A.B.: Oral azidothymidine, continuous infusion 5-fluorouracil and oral leucovorin: A phase I study. *J. Natl. Cancer Inst.* 82:1710-1714, 1990.
51. Curt, G.A.: Unsound methods of cancer treatment. In DeVita, V.T., Hellman, S. and Rosenberg, S.A. (Eds.), *Cancer; Principles and Practice of Oncology*, 4th Edition, J. B. Lippincott Co, pp. 2734-2747, 1993.
52. Pluda, J.M., Brawley, O.W., Yarchoan, R., Curt, G.A. and Broder, S.: Neoplasms associated with AIDS. In *Medical Oncology Basic Principles and Clinical Management of Cancer*, Calabresi, P. and Schein, P.S. (Eds.) McGraw Hill, Inc., New York. Second Edition, pp. 1173-1201, 1993.
53. Curt, G.A.: Drug resistance as a biochemical target in cancer chemotherapy. Vol. 13 *Bristol-Myers Squibb Cancer Symposia Series* (Tsuru, T. and Ogawa, M. eds) Academic Press in 1992.
54. Khleif, S.N. and Curt, G.A.: Animal models in cancer drug discovery and development. In *Cancer Medicine* (Holland, J. and Frei, E., Eds.) Third Edition, pp. 653-666, 1993.
55. Browne, M.J., Chafee, S., Dudley, M.N., Posner, M.R., Steinberg, S.M., Graham, K.K., Geletko, S.M., Zinner, S.H., Denman, S.L., Dunkle, L.M., Jaul, S., McLaren, C., Skowron, G., Kouttab, N.M., Kennedy, T.A., Weitberg, A.B. and Curt, G.A.: 2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: A phase I trial. *J. Infect. Disease* pp. 21-29, 1993.
56. Goldspiel, B.R. and Curt, G.A.: Issues in Antiemetic Therapy. Editorial, *Cancer*. Vol. 077:05, pp. 832-826, 1996.
57. Jenkins, J. and Curt, G.A.: Implementation of Clinical Trials. In McCorkle, R.,

Grant, M., Frank-Stromberg, M., Baird, S. **Cancer Nursing Comprehensive Textbook, 2nd Edition, Philadelphia, W.D. Saunders, pp. 470-484, 1996.**

58. **Curt, GA: Cancer Drug Development: New Targets for Cancer Treatment. *The Oncologist*, 1: 120, 1996**
59. **Kyle, E., Neckers, L., Takimoto, C., Curt, G. and Bergan, R.: Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity. *Molecular Pharmacology* 51 (2), 193-200, 1997.**
60. **Curt, GA: Investment in Research as a National Priority. *The Oncologist*, 3:1, 1998.**
61. **Curt, GA: 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy: Dutch Treat Revisited. *The Oncologist*, 3: 267-268, 1998.**
62. **Curt, GA: The Evolving Face of Palliative Care in Cancer Medicine. *The Oncologist* 4: 0, 1999.**
63. **Curt GA: The Impact of Fatigue on Patients with Cancer: Overview of Fatigue 1 and 2. *The Oncologist* 5: 9-12, 2000.**
64. **Sparber, A., Bauer, L., Curt, G., Eisenberg, D., Levin, T., Parks, S., Steinberg, S.M. and Wootton, J.K. Use of Complementary Medicine by Adult Patients Participating in Cancer Clinical Trials. *Oncology Nursing Forum*. Vol 27. No. 4 pp.623-630, 2000.**
65. **Curt, G A.: Breitbart, W., Cella, D., Groopman, J.E., Horning, S.J., Itri, L.M., Johnson, D.H., Miaskowski, C., Scherr, S.L., Portenoy, R.K. and Vogelzang, N.J.: Impact of Cancer-Related Fatigue on the Lives of Patients: New Findings from the Fatigue Coalition. *The Oncologist* 5:353-360, 2000.**
66. **Sparber, A., Wootton, J.C., Bauer, L., Curt, G., Eisenberg, D., Levin, T. and Steinberg, S.M.: Use of Complementary Medicine by Adult Patients Participating in HIV/AIDS Clinical Trials. *The Journal of Alternative and Complementary Medicine*.Vol.6, 5:415-422, 2000.**
67. **Curt, GA: Cancer and Terrorism. *The Oncologist* 6: 401, 2001.**
68. **Curt, GA: CME Online: From the Oncologist, For the Oncologist, *The Oncologist*, 6: 486, 2001.**
69. **Fox, E., Balis, F. and Curt GA: Clinical Trial Design for Target-Based Therapy. *The Oncologist*, 7: 401-409, 2002.**
70. **Curt, GA: Surveillance, Epidemiology and End Results Program: Report Card to**

the Nation. *The Oncologist*, 10: 1634, 2003.

71. **Curt, GA: A Masterpiece: The Life of Paul Calabresi (In Memoriam). *The Oncologist*, 8: 601, 2003.**
73. **Gulley J, and Curt GA: Targeted Therapy, in *The Bethesda Handbook of Cancer Treatment*, Eds, Abraham, J and Allegra C, Lippincott, Williams and Williams, in press.**

**APPEARS THIS WAY
ON ORIGINAL**